Interleukin-6

Drug Profile

Interleukin-6

Alternative Names: BCDF; Interferon-beta-2; interferon-β - 2; rhIL-6; β - 2 IF

Latest Information Update: 07 Oct 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cangene Corporation
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bacterial infections; Chemotherapy-induced damage; Thrombocytopenia

Most Recent Events

  • 07 Oct 2002 Discontinued - Phase-I for Chemotherapy induced damage in France and Switzerland (SC)
  • 07 Oct 2002 Discontinued - Phase-I for Thrombocytopenia (Chemotherapy-induced) in France and Switzerland (SC)
  • 07 Oct 2002 Discontinued - Preclinical for Bacterial infections in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top